Clinical research jobs providers UCB and Nodality have revealed they are to collaborate, with the latter firm's proprietary Single Cell Network Profiling (SCNP) technology set to be used to assist the development of several UCB compounds.
Although the exact terms of the agreement between the two companies has not been revealed, it will take place over a number of years and see payments made for success-based milestones, if all applicable development, regulatory and commercialisation milestones are achieved, while research and development funding is also going to be provided.
Dr David Parkinson, chief executive officer of Nodality, stated he is "delighted" to be announcing the collaboration between the two clinical research companies, adding: "Based on Nodality's extensive application of the SCNP platform to malignant and autoimmune diseases, we believe that we will be able to add significant value to UCB's drug development portfolio."
This comes shortly after UCB revealed it is to team up with Astellas to work on the development and commercialisation of Cimzia, a rheumatoid arthritis treatment that is to be marketed in Japan.